Yunna Jiang, MD
Endocrinology, Diabetes & Metabolism · Memphis, TNNPI 1831415058
Payments from drug & device makers
What this record shows
Almost everything reported here is food and beverage — 93.5% of the total across 593 separate payments, which is the pattern of a clinician who attends manufacturer presentations rather than one with a consulting arrangement. It is spread thinly across 48 manufacturers, the largest accounting for just 11.9% — the pattern of someone who eats at a lot of different presentations. 2025 is the largest year on record at $2,952, more than ten times the $138 reported in 2019.
Across 593 payments — averaging $20.64 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Lilly USA, LLC$1K
- Novo Nordisk$1K
- Senseonics, Incorporated$800
- Sanofi-aventis U.S. LLC$766
- Xeris Pharmaceuticals, Inc.$763
- Amgen$706
- plus $6K from 42 others
What the payments were for
- Speaking & faculty fees$8007%
- Food & beverage$11,44093%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
- Eversense$800
- CeQur Simplicity$485
- FARXIGA$126
How this compares
$12,240 in reported general payments places this provider in the 70th percentile of 130 endocrinology, diabetes & metabolism providers in Tennessee.
See all endocrinology, diabetes & metabolism providers in Tennessee →
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| OzempicSemaglutide | 176 | $278,146 |
| JardianceEmpagliflozin | 194 | $228,980 |
| Tresiba Flextouch U-200Insulin Degludec | 75 | $102,942 |
| MounjaroTirzepatide | 53 | $98,569 |
| FarxigaDapagliflozin Propanediol | 82 | $98,301 |
| Toujeo Max SolostarInsulin Glargine,hum.Rec.Anlog | 70 | $85,047 |
| TrulicityDulaglutide | 57 | $80,151 |
| Tresiba Flextouch U-100Insulin Degludec | 138 | $73,254 |
| Soliqua 100-33Insulin Glargine/Lixisenatide | 51 | $67,777 |
| Novolog FlexpenInsulin Aspart | 128 | $41,613 |
| Humalog Kwikpen U-200Insulin Lispro | 22 | $39,366 |
| Fiasp FlextouchInsulin Aspart (Niacinamide) | 31 | $31,294 |
| Teriparatide | 12 | $27,999 |
| Repatha SureclickEvolocumab | 19 | $26,747 |
| Toujeo SolostarInsulin Glargine,hum.Rec.Anlog | 36 | $22,944 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| Novo NordiskOzempic, Novolog | $1,400 | $290,880201 claims |
| Boehringer IngelheimJardiance | $226 | $228,980194 claims |
| Lilly USA, LLCMounjaro, Trulicity, Insulin Lispro | $1,461 | $179,928127 claims |
| AstraZenecaFarxiga | $664 | $98,30182 claims |
| Sanofi-aventis U.S. LLCSoliqua 100-33 | $766 | $67,77751 claims |
| MerckJanuvia | $37 | $21,01321 claims |
| AmgenProlia | $706 | $20,43312 claims |
| AbbVieSynthroid | $307 | $20,251203 claims |
| Amneal Pharmaceuticals LLCLevothyroxine Sodium, Unithroid | $238 | $7,420572 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 70th percentile of 130 endocrinology, diabetes & metabolism providers in Tennessee.
Other endocrinology, diabetes & metabolism in Memphis
- Alan CohenMemphis$1.4M
- Shimon HararyMemphis$735K
- Samuel Dagogo-JackMemphis$407K
- Aidar GosmanovMemphis$138K
- Malini GuptaMemphis$91K
- Benjamin BrannickMemphis$84K
- Pedro VelasquezMemphis$21K
- Fariha SalmanMemphis$14K
- Maher GhawjiMemphis$13K
- Rabia RehmanMemphis$7K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.